poisar

Stocks · News reference

Minerva Neurosciences Q2 Adj. EPS $(0.10) Beats $(0.12) Estimate

Benzinga Newsdesk

Minerva Neurosciences (NASDAQ:NERV) reported quarterly losses of $(0.10) per share which beat the analyst consensus estimate of $(0.12) by 9.09 percent. This is a 76.74 percent increase over losses of $(0.43) per share

More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

NERV
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Na

    Minerva Neurosciences to Participate in Two Upcoming Investor Conferences

    Minerva Neurosciences announced participation in two upcoming investor conferences (Wells Fargo Healthcare Conference on September 8 and Cantor Global Healthcare Conference on September 9, 2026). The company is conducting a confirmatory Phase 3 trial of roluperidone for negative symptoms of schizophrenia, with topline efficacy data expected in the second half of 2027. The company has also established a Scientific Advisory Board of leading experts in psychiatry and neuroscience.

    NERV